NR3C2 and hydrops fetalis: Therefore, the 2021 European Society of Cardiology as well as the 2022 American Heart Association/American College of Cardiology guidelines confirm the class I indication for mineralocorticoid receptor antagonist in patients with HF and a reduced left ventricular ejection fraction [22,23].